**IMPA2 polymorphisms and risk of ischemic stroke in a northwest Han Chinese population**

Qiaoya Ma¹, Ying Yang¹, Yuyan Na², Tianbo Jin³, Yidong Xue⁴, Yuting Shi⁵, Chen Li¹, Wanggang Zhang⁶

¹Department of Geriatrics Neurology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, P. R. China
²Department of Orthopaedics, Graduate School of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, P. R. China
³Department of Biochemistry, School of Life Sciences, Northwest University, Xi’an, Shanxi, P. R. China
⁴Department of Neurology, The Affiliated Hospital of Yan’an University, Yan’an, Shanxi, P. R. China
⁵Department of Medical Oncology, Graduate School of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, P. R. China
⁶Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi, P. R. China

**Correspondence to:** Chen Li, email: 364522490@qq.com
Wanggang Zhang, email: 18629647763@163.com

**Keywords:** ischemic stroke (IS), single nucleotide polymorphisms (SNPs), inositol monophosphatase 2 (IMPA2), case-control study

**Received:** June 29, 2016  **Accepted:** September 05, 2016  **Published:** September 20, 2016

**ABSTRACT**

Genetic association analysis has suggested that IMPA2 is a susceptibility gene for ischemic stroke (IS). To explore the association between IMPA2 polymorphisms and the risk of IS in a Han Chinese population, candidate gene association was performed using data from a case-control study of 488 IS patients and 503 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the association, and associations were evaluated under dominant, recessive, and additive genetic models using PLINK software. There was a statistically significant difference in the “TC” genotype frequency of the IMPA2 polymorphism rs589247, between cases and controls (50.0% vs. 45.3%). Under the dominant model, rs589247 was associated with an increased risk of IS (OR=1.32, 95%CI: 1.01-1.73; \( P=0.040 \)). There were no other associations between any of the seven additional IMPA2 polymorphisms and IS risk. This study is the first to find a correlation between an IMPA2 polymorphism and IS risk in a northwest Han Chinese population. These results may help to elucidate the molecular pathogenesis of this disease, and could potentially be used to predict IS risk. However, further studies are still needed to validate this association in other populations and with larger sample sizes.

**INTRODUCTION**

Ischemic stroke (IS) is a leading cause of death and disability [1]. Worldwide, approximately 15 million individuals suffer from stroke every year, and at least 80% of them are IS patients. IS is the result of interrupted blood flow within the area of an occluded blood vessel, causing local brain tissues to become short of oxygen, ending in malacia and necrosis [2]. There are various pathophysiological causes of IS, including atherothrombosis and embolism [3]. While IS can affect both men and women at any time of life, it is more prevalent in men over 45 years of age [4]. In addition, some rare IS syndromes, such as cerebral autosomal dominant with subcortical infarcts and leukoencephalopathy (CADASIL) syndrome, Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, and Fabry disease, mainly occur in young and middle-aged men [5]. Because of the high cost of IS treatment and medical rehabilitation, the preferred approach would be primary prevention through the identification of genetic and environmental contributions to IS risk.

IS is a complex and heterogeneous disease influenced by both genetic and environmental factors [6, 7]. Common risk factors for IS are older age, hypertension, diabetes mellitus, hyperlipidemia, smoking, and atrial fibrillation [8]. Beyond these risk factors, many
Table 1: Allele distribution in cases and controls and odds ratio estimates for ischemic stroke

| SNPs       | Chromosome | Position | Minor allele | Minor allele distribution | OR(95%CI) | P     | HWE P value |
|------------|------------|----------|--------------|---------------------------|-----------|-------|-------------|
| rs7506045  | 18p11.21   | 11987272 | T            | 240 (0.25) 266 (0.26)    | 0.91 (0.74-1.11) | 0.358 | 0.566       |
| rs589247   | 18p11.21   | 11992725 | T            | 448 (0.46) 424 (0.42)    | 1.16 (0.98-1.39) | 0.092 | 0.120       |
| rs669838   | 18p11.21   | 11994598 | C            | 444 (0.46) 422 (0.42)    | 1.15 (0.97-1.38) | 0.112 | 0.120       |
| rs636173   | 18p11.21   | 11996337 | G            | 444 (0.46) 418 (0.42)    | 1.18 (0.99-1.41) | 0.070 | 0.199       |
| rs3786285  | 18p11.21   | 12008847 | G            | 424 (0.44) 448 (0.45)    | 0.96 (0.81-1.15) | 0.199 | 0.126       |
| rs1020294  | 18p11.21   | 12017343 | G            | 186 (0.19) 167 (0.16)    | 1.18 (0.93-1.48) | 0.165 | 0.197       |
| rs1250171  | 18p11.21   | 12027028 | C            | 214 (0.22) 231 (0.23)    | 0.94 (0.76-1.16) | 0.564 | 0.313       |
| rs613993   | 18p11.21   | 12028580 | A            | 206 (0.21) 227 (0.23)    | 0.92 (0.74-1.13) | 0.419 | 0.307       |

HWE: Hardy-Weinberg equilibrium; OR: odds ratio; 95%CI: 95% confidence interval.
P values were calculated from Chi-square test/Fisher’s exact test.

RESULTS

Candidate genes for this illness have been investigated with numerous significant associations, such as variants in APOD in Swedish populations [9], KCNK17 in Spanish populations [10], and APOA5 in Han Chinese populations [11, 12]. These candidate genes may have a more prominent influence on disease onset when environmental factors have not yet had sufficient time to modify the phenotype. In complex diseases, population-based association studies provide more statistical power than family-based linkage studies [13]. Therefore, in the present study, candidate gene association was adopted to find genetic polymorphisms implicated in IS.

IMPA2, located on chromosome 18p11.2, encodes myo-inositol monophosphatase 2, which is involved in the phosphatidylinositol signaling pathway [14]. This gene was identified as a febrile seizure susceptibility gene [15], but is also associated with neuropsychiatric disorders, such as bipolar disorder. Carriers of the “AA” genotype for IMPA2 rs669838 are also more likely to have a history of suicide attempts in comparison to C-allele carriers [16], and IMPA2 or a nearby gene may contribute to the overall genetic risk for schizophrenia [17]. In 2007, a genome-wide association study (GWAS) showed that IMPA2 polymorphisms are associated with IS in an American population [18]. We wanted to know whether these findings could be reproduced in a Han Chinese population. Therefore, eight IMPA2 SNPs (rs7506045, rs589247, rs669838, rs636173, rs3786385, rs1020294, rs1250171, and rs613993) that had been investigated for bipolar disorder and/or IS with minor allele frequencies (MAF) >5% in a Han Chinese Beijing population were selected to investigate their potential correlations.

DISCUSSION

To investigate whether SNPs in IMPA2 influence IS susceptibility in a Han Chinese population, we performed a candidate gene association study using a case-control
The association of IMPA2 with IS was previously reported in a GWAS by Matarin et al. [18] We found a significant association with IS risk was for rs589247 under both a genotype model and a dominant model. This result suggests that rs589247 in the IMPA2 gene may confer risk for IS under a dominant model.

Myo-inositol monophosphatase 2, which is encoded by the IMPA2 gene, converts inositol phosphate into inositol through dephosphorylation. Inositol is an essential intracellular signaling molecule in second messenger pathways that may exert an insulin-like effect and improve blood pressure, cholesterol, high-density lipoprotein, and triglyceride levels which are all involved in the pathogenesis of IS [19]. We found that the IMPA2 rs589247 polymorphism was associated with an increased risk of IS. Thus, it is possible that this SNP inhibits Myo-inositol monophosphatase expression, thereby contributing to a predisposition for IS.

In the GWAS of IS patients conducted by Matarin et al., there was no significant association between rs7506045 and IS susceptibility in an American population after Bonferroni correction [18]. Three years later, Domingues-Montanari and colleagues analyzed the same relationship in a Spanish Caucasian population comprised of IS patients and healthy controls, and found that IMPA2 rs7506045 was associated with a statistically significant increase (1.57-fold) in IS susceptibility under an additive model [10]. However, we did not observe any significant

| SNP    | Models | Genotype | Genotype frequency | OR (95%CI) | P* | P# |
|--------|--------|----------|--------------------|------------|----|----|
| rs589247 | Genotype | CC | 177 | 142 | 1.000 |
|        | TC     | 228 | 244 | 1.33 (1.00-1.77) | 0.048* | 1 |
|        | TT     | 98  | 102 | 1.30 (0.91-1.85) | 0.150 | 1 |
|        | Dominant | TT+TC | 326 | 346 | 1.32 (1.01-1.73) | 0.040* | 1 |
|        | CC     | 177 | 142 | 1.000 |
|        | Recessive | TT | 98  | 102 | 1.09 (0.80-1.49) | 0.578 | 1 |
|        | TC+CC  | 405 | 386 | 1.000 |
|        | Additive | - | - | 1.16 (0.97-1.38) | 0.098 | 1 |

SNPs, single-nucleotide polymorphisms; OR, odds ratio; 95%CI, 95% confidence interval. *P values were calculated from unconditional logistic regression analysis. **P values were adjusted by Bonferroni correction. *P≤0.05 indicates statistical significance.

| Haplotype block | Haplotype frequency | OR (95%CI) | Chi-square | P   |
|-----------------|---------------------|------------|------------|-----|
| rs7506045-rs589247-rs669838-rs636173 | C-T-C-G | 0.454 | 0.412 | 1.18 (0.99-1.40) | 3.402 | 0.065 |
|                | T-C-A-A | 0.243 | 0.259 | 0.92 (0.75-1.13) | 0.688 | 0.407 |
|                | C-C-A-A | 0.293 | 0.316 | 0.90 (0.74-1.09) | 1.162 | 0.281 |
| rs1250171-rs613993 | C-A | 0.210 | 0.227 | 0.91 (0.73-1.12) | 0.789 | 0.374 |
|                | T-G | 0.780 | 0.771 | 1.06 (0.85-1.30) | 0.243 | 0.622 |

OR, odds ratio; 95%CI, 95% confidence interval. P values were calculated from unconditional logistic regression analysis.
relationship between IMPA2 rs7506045 and IS risk using an additive model analysis (OR=0.91, 95% CI: 0.75-1.11; \(P=0.363\)). This difference in results may be due to the different ethnicity of our subjects, and/or to inadequate statistical power. Ding et al. previously carried out a study to confirm the GWAS variants reported by Matarin et al. in a Han Chinese population from Wuhan, China [20]. Consistent with our findings, they did not find a significant association of rs7506045 with IS risk under an additive model (OR=1.21, 95% CI: 0.95-1.53; \(P=0.128\)). Taken together, these data provide support for the notion that rs7506045 in IMPA2 might have different effects on IS risk in different populations.

To our knowledge, this study is the first to investigate the potential association of IMPA2 polymorphisms with IS risk in a northwest Han Chinese population, and is the first to explore several novel variants in IMPA2 in IS. We found rs589247 was associated with increased risk of IS under a genotype model and a dominant model. However, none of our results remained significant after Bonferroni correction. This correction might be overly conservative, or the limited sample size in our study might cause a negative result. In addition to the small sample size, our study has other limitations that should be mentioned. First, we did not take into consideration the association of conventional risk factors, such as smoking, hypertension, obesity, elevated triglyceride and cholesterol levels, diabetes mellitus and dyslipidemia, for IS risk with IMPA2 polymorphisms. Second, there may be other SNPs on 18p11.21 that are related to IS risk but were not assessed for their potential associations.

In conclusion, our study provides evidence for a potential association of rs589247 in the IMPA2 gene with increased risk of IS. However, it is unclear whether this finding will be reproduced in other populations. Therefore, more detailed functional and epidemiological studies in larger populations are still needed to validate the association of IMPA2 variants in the development of IS.

**MATERIALS AND METHODS**

**Study subjects**

A total of 488 patients (mean age: 63.96 years, 66.6% male) with IS were enrolled from the Geriatric Neurology Department of the Second Affiliated Hospital of Xi’an Jiaotong University and the Neurology Department of the Affiliated Hospital of Yan’an University from February 2013 to December 2015. All individuals involved in this study gave written consent for genetic analysis. All participants underwent a detailed medical history interview and physical examination. Examination were used to confirm the diagnosis of IS according to the International Classification of Disease; (2) Blood samples were drawn from ethnic Han Chinese population who were genetically unrelated within Northwest China; (3) None had a history of other types of stroke (transient ischemic attack and subarachnoid hemorrhage), cerebral vein thrombosis, Parkinson’s disease, Alzheimer’s disease, bipolar disorder, or brain aneurysm; (4) Subjects with cardiogenic thrombosis and atrial fibrillation which may contribute to the development of IS were also excluded. As a control group, 503 ethically and geographically matched and neurologically normal inpatient individuals were randomly recruited from various departments of the Second Affiliated Hospital of Xi’an Jiaotong University. The study protocol was approved by the ethical committee of the Second Affiliated Hospital of Xi’an Jiaotong University and the Affiliated Hospital of Yan’an University.

**DNA isolation and genotyping**

Peripheral blood (5 ml) was collected from each subject into tubes containing ethylenediaminetetraacetic acid to prevent clotting. After centrifugation, the samples were kept at -80°C until further use. Genomic DNA was extracted from peripheral blood samples using the GoldMag-Mini Purification Kit (GoldMag Co. Ltd. Xi’an city, China) according to the manufacturer’s instructions. DNA concentrations were measured using a NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). DNA was diluted using QIAgility to a final concentration of 20 ng/μl. Eight SNPs in the IMPA2 gene with a minor allele frequency (MAF) >5% in a Han Chinese Beijing population were selected for genotyping using the HapMap database. Sequenom Mass ARRAY Design 3.0 Software (Sequenom Co. Ltd, San Diego, California, USA) was used to design a Multiplexed SNP MassEXTEND assay. PCR primers for the eight selected SNPs are listed in Supplementary Table 1. SNP genotyping was carried out by using the Sequenom Mass ARRAY RS1000 [21]. Data were managed and analyzed with SequenomTyper 4.0 Software (Sequenom Co. Ltd) [21, 22].

**Statistical analysis**

Statistical analysis was conducted using Microsoft Excel and SPSS 16.0 (SPSS, Chicago IL USA). Statistical significance was set at a two-sided \(P<0.05\). Fisher's exact tests were used to test for deviation from Hardy-Weinberg equilibrium. The distributions of genotype and allele of each SNP were compared using unconditional logistic regression analysis and Chi-square/Fisher's exact tests in cases and controls. Odds ratio (OR) and 95% confidence intervals (CI) were used to assess the effect of each polymorphism and IS risk [23]. All association
analysis were conducted under three genetic models: dominant, recessive, and additive using PLINK software (http://pngu.mgh.harvard.edu/purcell/plink/). In addition, the SHEsis software platform (http://analysis.bio-x.cn/myAnalysis.php) and Haplovie software package (version 4.2) were used to analyze and visualize patterns of linkage disequilibrium (LD) and haplotype maps [24, 25]. Haplotype blocks were identified using the solid spine of LD method in Haplovie.

ACKNOWLEDGMENTS

We thank all the patients and individuals for their participation and all the neurological physicians in the Neurology Department of the Affiliated Hospital of Yan’an University for their donations of ischemic stroke blood samples.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

GRANT SUPPORT

This work was supported by the Youth Science Foundation (YJ(QN)201307) and Key Project (YJ(ZD)201404) of the Second Affiliated Hospital of Xi’an Jiaotong University, Youth Science Foundation of Xi’an Jiaotong University (xjj2014082), Natural Science Foundation of Shaanxi Government (2015JQ8319).

REFERENCES

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012; 125:188-197.

2. Keum S, Lee HK, Chu PL, Kan MJ, Huang MN, Gallione CJ, Gunn MD, Lo DC, Marchuk DA. Natural genetic variation of integrin alpha L (Itgal) modulates ischemic brain injury in stroke. PLoS genetics. 2013; 9:e1003807.

3. Kvasnicka T. [The Association of atherothrombosis and thrombophilias - genetic aspects]. Vnitrni lekarstvi. 2014; 60:880-884.

4. Barker-Collo S, Bennett DA, Krishnamurthi RV, Parmar P, Feigin VL, Naghavi M, Forouzanfar MH, Johnson CO, Nguyen G, Mensah GA, Vos T, Murray CJ, Roth GA. Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology. 2015; 45:203-214.

5. Bersano A, Borellini L, Motto C, Lanfranconi S, Pezzini A, Basilico P, Miceli G, Padovani A, Parati E, Candelise L. Molecular basis of young ischemic stroke. Current medicinal chemistry. 2013; 20:3818-3839.

6. Liu Y, Ma Y, Zhang B, Wang SX, Wang XM, Yu JM. Genetic polymorphisms in pre-microRNAs and risk of ischemic stroke in a Chinese population. Journal of molecular neuroscience: MN. 2014; 52:473-480.

7. Soriano-Tarraga C, Jimenez-Conde J, Giralt-Steinhauer E, Mola M, Ois A, Rodriguez-Campello A, Cuadrado-Godia E, Fernandez-Cadenas I, Carrera C, Montaner J, Elosua R, Roquer J. Global DNA methylation of ischemic stroke subtypes. PloS one. 2014; 9:e96543.

8. Ankolekar S, Rewell S, Howells DW, Bath PM. The influence of stroke risk factors and comorbidities on assessment of stroke therapies in humans and animals. International journal of stroke. 2012; 7:386-397.

9. Lovkvist H, Jonsson AC, Luthman H, Jood K, Jern C, Wieloch T, Lindgren A. Variations in apolipoprotein D and sigma non-opioid intracellular receptor 1 genes with relation to risk, severity and outcome of ischemic stroke. BMC neurology. 2014; 14:191.

10. Domingues-Montanari S, Fernandez-Cadenas I, Del Rio-Espinola A, Mendioroz M, Fernandez-Moraes J, Corbeto N, Delgado P, Ribo M, Rubiera M, Obach V, Marti-Fabregas J, Freijo M, Serena J, Montaner J. KCNN7 genetic variants in ischemic stroke. Atherosclerosis. 2010; 208:203-209.

11. Li X, Su D, Zhang X, Zhang C. Association of apolipoprotein A5 gene promoter region-1131T>C with risk of stroke in Han Chinese. European journal of internal medicine. 2011; 22:99-102.

12. Pi Y, Zhang L, Yang Q, Li B, Guo L, Fang C, Gao C, Wang J, Xiang J, Li J. Apolipoprotein A5 gene promoter region-1131T/C polymorphism is associated with risk of ischemic stroke and elevated triglyceride levels: a meta-analysis. Cerebrovascular diseases (Basel, Switzerland). 2012; 33:558-565.

13. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science (New York, NY). 1996; 273:1516-1517.

14. Fujita S, Ohnishi T, Okuda S, Kobayashi R, Fukuno S, Furuta D, Kikuchi T, Yoshikawa T, Fujita N. In silico study on the substrate binding manner in human myo-inositol monophosphatase 2. Journal of molecular modeling. 2011; 273:1516-1517.

15. Nakayama J, Yamamoto N, Hamano K, Iwasaki N, Ohta M, Nakahara S, Matsui A, Noguchi E, Arinami T. Linkage and association of febrile seizures to the IMPA2 gene on human chromosome 18. Neurology. 2004; 63:1803-1807.

16. Jimenez E, Arias B, Mitjans M, Goikolea JM, Roda E, Saiz PA, Garcia-Portilla MP, Buron P, Bobes J, Oquendo MA, Vieta E, Benabarre A. Genetic variability at IMPA2, INPP1 and GSK3beta increases the risk of suicidal behavior in bipolar patients. European neuropsychopharmacology:
17. Yoshikawa T, Kikuchi M, Saito K, Watanabe A, Yamada K, Shibuya H, Nankai M, Kurumaji A, Hattori E, Ishiguro H, Shimizu H, Okubo Y, Toru M, Detera-Wadleigh SD. Evidence for association of the myo-inositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples. Molecular psychiatry. 2001; 6:202-210.

18. Matarin M, Brown WM, Scholz S, Simon-Sanchez J, Fung HC, Hernandez D, Gibbs JR, De Vrieze FW, Crews C, Britton A, Langefeld CD, Brott TG, Brown RD, Jr., et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 2007; 6:414-420.

19. Santamaria A, Giordano D, Corrado F, Pintaudi B, Interdonato ML, Vieste GD, Benedetto AD, D'Anna R. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric: the journal of the International Menopause Society. 2012; 15:490-495.

20. Ding H, Xu Y, Bao X, Wang X, Cui G, Wang W, Hui R, Wang DW. Confirmation of genomewide association signals in Chinese Han population reveals risk loci for ischemic stroke. Stroke; a journal of cerebral circulation. 2010; 41:177-180.

21. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Current protocols in human genetics/editorial board, Jonathan L Haines [et al]. 2009; Chapter 2:Unit 2.12.

22. Thomas RK, Baker AC, DeBiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007; 39:347-351.

23. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ (Clinical research ed). 2000; 320:1468.

24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England). 2005; 21:263-265.

25. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15:97-98.